Addex Pharmaceuticals (ADDXF.PK) said that ADX71943 has demonstrated statistically significant analgesic-like effects in three preclinical models of pain.
ADX71943 is an orally available positive allosteric modulator of the GABA(B) receptor that has potential for treatment of osteoarthritis pain and chronic nociceptive pain as well as other indications.
In the first model, ADX71943 reversed complete Freund adjuvant-induced reductions in withdrawal thresholds in a dose-related manner, with a minimum statistically significant effective oral dose of 10 mg/kg. In a second model (Formalin test), ADX71943 showed anti-nociceptive effect after oral administration of 3 to 10 mg/kg. In a third model, an increased visceral pain threshold was seen using ADX71943 with a minimum statistically significant effective dose between 3 and 10 mg/kg.
Further, the company noted that ADX71943 has a good developability profile and is expected to enter clinical testing in the fourth quarter 2010.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.